Feminox 40 PFS Injection is a vital medication used in modern thromboprophylaxis and treatment. This formulation contains Enoxaparin, a low molecular weight heparin (LMWH) that offers several significant clinical and pharmacokinetic advantages over unfractionated heparin (UFH). The key composition of Feminox 40 PFS Injection includes Enoxaparin sodium, which is known for its longer plasma half-life, predictable dose-response, and a lower risk of Heparin-Induced Thrombocytopenia (HIT). The primary purpose of Feminox 40 PFS Injection is to prevent and treat blood clots, particularly in patients at moderate to high risk of developing deep vein thrombosis (DVT) or pulmonary embolism (PE). As part of the therapeutic category of anticoagulants, Feminox 40 PFS Injection plays a crucial role in managing conditions that require effective blood thinning to prevent clot formation. By inhibiting specific clotting factors, Feminox 40 PFS Injection helps maintain proper blood flow and reduces the risk of serious complications associated with thrombosis. The formulation is designed for subcutaneous administration, making it convenient for both healthcare providers and patients. With its proven efficacy and safety profile, Feminox 40 PFS Injection is an essential tool in the prevention and management of thromboembolic events. The active components of Feminox 40 PFS Injection work synergistically to support mineral balance and absorption, influencing nerve conduction, muscle function, hydration, and metabolic activity. This comprehensive approach ensures that patients receive optimal care while minimizing the risks associated with anticoagulation therapy. Overall, Feminox 40 PFS Injection is a critical component in the arsenal against thromboembolic disorders, providing healthcare professionals with a reliable option for patient management.
Uses & Benefits
Feminox 40 PFS Injection provides high efficacy and predictable response in anticoagulation therapy.
This formulation is effective in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
Feminox 40 PFS Injection simplifies patient management by eliminating the need for routine laboratory monitoring.
The convenience of once-daily subcutaneous injection enhances patient compliance.
Feminox 40 PFS Injection has a lower risk of Heparin-Induced Thrombocytopenia (HIT) compared to unfractionated heparin.
This medication is essential for prophylaxis in high-risk settings, such as major surgeries or immobilized patients.
Feminox 40 PFS Injection supports early hospital discharge by allowing for continued prophylaxis at home.
It is suitable for patients with established DVT or PE when higher therapeutic doses are required.
Feminox 40 PFS Injection is effective in managing acute coronary syndrome by preventing clot formation.
This formulation aids in maintaining proper blood flow during critical medical conditions.
Feminox 40 PFS Injection is beneficial for patients undergoing high-risk general surgery.
The predictable pharmacokinetics of Feminox 40 PFS Injection reduce the complexity of anticoagulation management.
How Feminox 40 PFS Injection works
Feminox 40 PFS Injection operates primarily through its interaction with antithrombin, enhancing its ability to inhibit clotting factors. This mechanism is crucial for its effectiveness as an anticoagulant.
Enoxaparin in Feminox 40 PFS Injection binds strongly to Antithrombin (AT), a key plasma protein responsible for neutralizing clotting factors.
The binding induces a conformational change in AT, significantly enhancing its inhibitory power against activated Factor X (Factor Xa).
By inhibiting Factor Xa, Feminox 40 PFS Injection effectively blocks the central amplification loop of the coagulation cascade.
This action prevents thrombin generation and fibrin clot formation, reducing the risk of thrombosis.
Feminox 40 PFS Injection exhibits minimal inhibition of thrombin (Factor IIa), contributing to its lower bleeding risk compared to UFH.
The selective action of Feminox 40 PFS Injection allows for a more predictable anticoagulant effect.
How to use Feminox 40 PFS Injection
The prophylactic dose of Feminox 40 PFS Injection is typically one pre-filled syringe (40mg/0.4 mL) administered once daily.
For treatment doses in established DVT or PE, higher doses such as 1 mg/kg every 12 hours may be required.
Administration should be done via deep subcutaneous injection only; do not administer intramuscularly or intravenously unless specified.
The preferred injection site for Feminox 40 PFS Injection is the abdominal wall, alternating between left and right sides.
Inject at least two inches away from the navel and avoid areas with skin folds or bruising.
Pinch a fold of skin during injection, insert the needle perpendicularly, inject the entire contents, and remove the needle without rubbing the site.
A small air bubble in the syringe should not be expelled before injection as it helps ensure full delivery of the dose.
Consistency in timing is important; administer Feminox 40 PFS Injection at the same time each day for optimal results.
Lifestyle Advice
Maintain proper injection technique to minimize bruising; inject deep under the skin without rubbing the site afterward.
Be vigilant for signs of unusual bleeding such as frequent nosebleeds or blood in urine/stool; report these immediately to your doctor.
Inform all healthcare providers about using Feminox 40 PFS Injection before any procedures or surgeries.
Avoid combining Feminox 40 PFS Injection with NSAIDs unless directed by a physician due to increased bleeding risk.
Store Feminox 40 PFS Injection at room temperature away from light and moisture; keep out of reach of children and pets.
Side Effects
Side Effects
Common side effects include localized bleeding or bruising at the injection site.
Injection site reactions may involve pain, redness, or irritation.
Elevated liver enzymes (AST/ALT) can occur but are usually transient and not clinically significant.
Thrombocytopenia may happen; however, severe HIT is rare with Feminox 40 PFS Injection.
Serious side effects include major hemorrhage; seek immediate medical attention if experiencing prolonged bleeding or blood in urine/stool.
Heparin-Induced Thrombocytopenia (HIT) can occur; monitor platelet counts during prolonged therapy.
Spinal or epidural hematoma is a rare but serious risk when used near spinal procedures; report any severe back pain or numbness immediately.
Allergic reactions may manifest as rash, hives, swelling, or difficulty breathing; seek urgent care if these symptoms occur.
Precautions and Warnings
People with kidney problems or severe liver disease should be careful and may need to change their dosage.
1. What is Feminox 40 PFS Injection used for?
Feminox 40 PFS Injection is primarily utilized for preventing and treating blood clots like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), especially after surgical procedures or during prolonged immobility.
2. Is Feminox 40 PFS Injection the same as Heparin?
No, Feminox 40 PFS Injection contains Enoxaparin, which is a Low Molecular Weight Heparin (LMWH). It has a more predictable effect and requires less monitoring compared to unfractionated heparin.
3. Can I use Feminox 40 PFS Injection if I have an existing blood clot?
The standard prophylactic dose of Feminox 40 PFS Injection does not treat existing clots. A higher therapeutic dose is necessary for treating established clots.
4. Where should I inject Feminox 40 PFS Injection?
The recommended injection site for Feminox 40 PFS Injection is deep subcutaneously into the abdominal wall, alternating between left and right sides.
5. Should I rub the injection site after administering Feminox 40 PFS Injection?
No, rubbing the injection site can increase bruising. It is advised to leave the site undisturbed after injection.
6. Why is there an air bubble in the syringe?
The air bubble in the syringe is intentional. It ensures that the entire dose is delivered effectively and creates an 'air lock' at the injection site.
7. Is it safe to take NSAIDs while using Feminox 40 PFS Injection?
Combining NSAIDs with Feminox 40 PFS Injection can significantly increase bleeding risks. Consult your doctor before taking any additional medications.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
Please refer to the product label for storage information.
SKU
16220
Country of Manufacture
India
Manufacturer Address
Intas Pharmaceuticals Ltd.
Return/Buy Back policy
Non-returnable
Prescription Required
Yes
Storage
Please refer to the product label for storage information.
Seller
Kogland Commerce Pvt Ltd (TN)
Feminox 40 PFS Injection is a vital medication used in modern thromboprophylaxis and treatment. This formulation contains Enoxaparin, a low molecular weight heparin (LMWH) that offers several significant clinical and pharmacokinetic advantages over unfractionated heparin (UFH). The key composition of Feminox 40 PFS Injection includes Enoxaparin sodium, which is known for its longer plasma half-life, predictable dose-response, and a lower risk of Heparin-Induced Thrombocytopenia (HIT). The primary purpose of Feminox 40 PFS Injection is to prevent and treat blood clots, particularly in patients at moderate to high risk of developing deep vein thrombosis (DVT) or pulmonary embolism (PE). As part of the therapeutic category of anticoagulants, Feminox 40 PFS Injection plays a crucial role in managing conditions that require effective blood thinning to prevent clot formation. By inhibiting specific clotting factors, Feminox 40 PFS Injection helps maintain proper blood flow and reduces the risk of serious complications associated with thrombosis. The formulation is designed for subcutaneous administration, making it convenient for both healthcare providers and patients. With its proven efficacy and safety profile, Feminox 40 PFS Injection is an essential tool in the prevention and management of thromboembolic events. The active components of Feminox 40 PFS Injection work synergistically to support mineral balance and absorption, influencing nerve conduction, muscle function, hydration, and metabolic activity. This comprehensive approach ensures that patients receive optimal care while minimizing the risks associated with anticoagulation therapy. Overall, Feminox 40 PFS Injection is a critical component in the arsenal against thromboembolic disorders, providing healthcare professionals with a reliable option for patient management.
Uses & Benefits
Feminox 40 PFS Injection provides high efficacy and predictable response in anticoagulation therapy.
This formulation is effective in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
Feminox 40 PFS Injection simplifies patient management by eliminating the need for routine laboratory monitoring.
The convenience of once-daily subcutaneous injection enhances patient compliance.
Feminox 40 PFS Injection has a lower risk of Heparin-Induced Thrombocytopenia (HIT) compared to unfractionated heparin.
This medication is essential for prophylaxis in high-risk settings, such as major surgeries or immobilized patients.
Feminox 40 PFS Injection supports early hospital discharge by allowing for continued prophylaxis at home.
It is suitable for patients with established DVT or PE when higher therapeutic doses are required.
Feminox 40 PFS Injection is effective in managing acute coronary syndrome by preventing clot formation.
This formulation aids in maintaining proper blood flow during critical medical conditions.
Feminox 40 PFS Injection is beneficial for patients undergoing high-risk general surgery.
The predictable pharmacokinetics of Feminox 40 PFS Injection reduce the complexity of anticoagulation management.
How Feminox 40 PFS Injection works
Feminox 40 PFS Injection operates primarily through its interaction with antithrombin, enhancing its ability to inhibit clotting factors. This mechanism is crucial for its effectiveness as an anticoagulant.
Enoxaparin in Feminox 40 PFS Injection binds strongly to Antithrombin (AT), a key plasma protein responsible for neutralizing clotting factors.
The binding induces a conformational change in AT, significantly enhancing its inhibitory power against activated Factor X (Factor Xa).
By inhibiting Factor Xa, Feminox 40 PFS Injection effectively blocks the central amplification loop of the coagulation cascade.
This action prevents thrombin generation and fibrin clot formation, reducing the risk of thrombosis.
Feminox 40 PFS Injection exhibits minimal inhibition of thrombin (Factor IIa), contributing to its lower bleeding risk compared to UFH.
The selective action of Feminox 40 PFS Injection allows for a more predictable anticoagulant effect.
How to use Feminox 40 PFS Injection
The prophylactic dose of Feminox 40 PFS Injection is typically one pre-filled syringe (40mg/0.4 mL) administered once daily.
For treatment doses in established DVT or PE, higher doses such as 1 mg/kg every 12 hours may be required.
Administration should be done via deep subcutaneous injection only; do not administer intramuscularly or intravenously unless specified.
The preferred injection site for Feminox 40 PFS Injection is the abdominal wall, alternating between left and right sides.
Inject at least two inches away from the navel and avoid areas with skin folds or bruising.
Pinch a fold of skin during injection, insert the needle perpendicularly, inject the entire contents, and remove the needle without rubbing the site.
A small air bubble in the syringe should not be expelled before injection as it helps ensure full delivery of the dose.
Consistency in timing is important; administer Feminox 40 PFS Injection at the same time each day for optimal results.
Lifestyle Advice
Maintain proper injection technique to minimize bruising; inject deep under the skin without rubbing the site afterward.
Be vigilant for signs of unusual bleeding such as frequent nosebleeds or blood in urine/stool; report these immediately to your doctor.
Inform all healthcare providers about using Feminox 40 PFS Injection before any procedures or surgeries.
Avoid combining Feminox 40 PFS Injection with NSAIDs unless directed by a physician due to increased bleeding risk.
Store Feminox 40 PFS Injection at room temperature away from light and moisture; keep out of reach of children and pets.
Side Effects
Side Effects
Common side effects include localized bleeding or bruising at the injection site.
Injection site reactions may involve pain, redness, or irritation.
Elevated liver enzymes (AST/ALT) can occur but are usually transient and not clinically significant.
Thrombocytopenia may happen; however, severe HIT is rare with Feminox 40 PFS Injection.
Serious side effects include major hemorrhage; seek immediate medical attention if experiencing prolonged bleeding or blood in urine/stool.
Heparin-Induced Thrombocytopenia (HIT) can occur; monitor platelet counts during prolonged therapy.
Spinal or epidural hematoma is a rare but serious risk when used near spinal procedures; report any severe back pain or numbness immediately.
Allergic reactions may manifest as rash, hives, swelling, or difficulty breathing; seek urgent care if these symptoms occur.
Precautions and Warnings
People with kidney problems or severe liver disease should be careful and may need to change their dosage.
1. What is Feminox 40 PFS Injection used for?
Feminox 40 PFS Injection is primarily utilized for preventing and treating blood clots like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), especially after surgical procedures or during prolonged immobility.
2. Is Feminox 40 PFS Injection the same as Heparin?
No, Feminox 40 PFS Injection contains Enoxaparin, which is a Low Molecular Weight Heparin (LMWH). It has a more predictable effect and requires less monitoring compared to unfractionated heparin.
3. Can I use Feminox 40 PFS Injection if I have an existing blood clot?
The standard prophylactic dose of Feminox 40 PFS Injection does not treat existing clots. A higher therapeutic dose is necessary for treating established clots.
4. Where should I inject Feminox 40 PFS Injection?
The recommended injection site for Feminox 40 PFS Injection is deep subcutaneously into the abdominal wall, alternating between left and right sides.
5. Should I rub the injection site after administering Feminox 40 PFS Injection?
No, rubbing the injection site can increase bruising. It is advised to leave the site undisturbed after injection.
6. Why is there an air bubble in the syringe?
The air bubble in the syringe is intentional. It ensures that the entire dose is delivered effectively and creates an 'air lock' at the injection site.
7. Is it safe to take NSAIDs while using Feminox 40 PFS Injection?
Combining NSAIDs with Feminox 40 PFS Injection can significantly increase bleeding risks. Consult your doctor before taking any additional medications.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
Please refer to the product label for storage information.
SKU
16220
Country of Manufacture
India
Manufacturer Address
Intas Pharmaceuticals Ltd.
Return/Buy Back policy
Non-returnable
Prescription Required
Yes
Storage
Please refer to the product label for storage information.
Seller
Kogland Commerce Pvt Ltd (TN)
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Related Products
Customer Reviews
No reviews yet
Be the first to share your thoughts. Honest feedback helps other shoppers and us serve you better.
